Dose modifications
Among patients who received nivolumab plus cabozantinib, 318 were included in the analysis to characterize the relationship between individual predicted cabozantinib CL/F and the rate of dose modifications (Supplementary Table S3); 285 had a dose modification. The exploratory KM plot for cabozantinib dose modification by CL/F quartiles (Fig. Kaplan–Meier plot for cabozantinib dose modification by individual predicted apparent clearance quartiles. Shaded regions represent 95% confidence intervals for each exposure quartile (Q#) of CL/F, the individual predicted apparent cabozantinib clearance from population pharmacokinetic model